AbbVie Buys Bowel Disease Biotech Celsius For $250M
By Al Barbarino · June 27, 2024, 5:15 PM EDT
Chicago-based pharmaceutical company AbbVie said Thursday it has acquired Celsius Therapeutics Inc., a privately held clinical-stage biotechnology company developing therapies for patients with inflammatory disease, for $250 million....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login